Neumora Therapeutics (NMRA) Change in Accured Expenses (2022 - 2026)

Neumora Therapeutics' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 339.43% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$1.5 million (down 111.54% YoY), while the FY2025 annual figure was $4.2 million, down 42.03% from the prior year.
• Change in Accured Expenses was -$4.0 million for Q1 2026 at Neumora Therapeutics, down from $4.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.6 million in Q3 2024 to a low of -$6.3 million in Q2 2025.
• Historically, Change in Accured Expenses has averaged $1.5 million across 5 years, with a median of $1.9 million in 2024.
• Biggest YoY gain for Change in Accured Expenses was 184.95% in 2024; the steepest drop was 458.83% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $7.0 million in 2022, then slumped by 130.73% to -$2.2 million in 2023, then soared by 184.95% to $1.8 million in 2024, then surged by 116.89% to $4.0 million in 2025, then sank by 201.01% to -$4.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.0 million (Q1 2026), $4.0 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.